Navigation Links
EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical results for its Aurora kinase - angiogenesis inhibitor, ENMD-981693. The data were presented during oral and poster presentations by EntreMed scientists at the 2nd Protein Kinases in Drug Discovery Conference being held May 31 - June 1, 2007 in Boston, Massachusetts.

ENMD-981693 is an oral, dual-acting kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. In preclinical studies, ENMD-981693 has been shown to inhibit a unique profile of angiogenic tyrosine kinase targets in addition to the Aurora kinases. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-981693 is selective for the Aurora A isoform in comparison to Aurora B.

Results from in vitro studies demonstrate ENMD-981693's potent activity against oncogenic receptor tyrosine kinases, including FLT3, c-Kit and CSF1R, which are involved in the pathology of hematological cancers. Additionally, ENMD-981693 demonstrated potent inhibition of a spectrum of targets linked to angiogenesis, including KDR (VEGFR2) and FGFR1. The compound was also shown to induce apoptosis and cell cycle arrest in a broad range of cell lines.

ENMD-981693 exhibited antiangiogenic activity in in vivo animal models by preventing the formation of new blood vessels and inducing regression of formed vessels at well-tolerated doses. Orally-administered ENMD-981693 induced tumor regression with minimal toxicity in a preclinical xenograft model of human leukemia. This activity is consistent with tumor regression induced by ENMD-981693 in preclinical models of human tumors derived from colon, leukemia, and breast cancer cell lines.

Mark R. Bray, Ph.D., Vice President, Research at EntreMed, commented on the presentations, "Results from these preclinical studies highlight the tremendous progress we have made with this compound and further support our selection of ENMD-981693 as the lead for our Aurora kinase program. ENMD-981693 has been shown to induce tumor regression in multiple preclinical models, which demonstrates the compound's potential clinical utility in a broad variety of cancers. IND-directed studies are currently underway and we anticipate the filing of an IND for ENMD-981693 in the fourth quarter of 2007."

To view the presentations, visit the Recent Presentations section of the Company's web site at

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in multiple Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell-cycle regulator, is in various Phase 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for fu ture financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).


     Ginny Dunn

     EntreMed, Inc.

     Associate Director

     Corporate Communications &

     Investor Relations

     (240) 864-2643

CONTACT: Ginny Dunn, Associate Director Corporate Communications &Investor Relations, of EntreMed, Inc., +1-240-864-2643

Web site:

Ticker Symbol: (NASDAQ-NMS:ENMD)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
5. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
6. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Eli Lilly and Company ... square feet and approximately 50 new jobs to its research ... New York, New York . ... 2016, this space will include a translational immuno-oncology hub and ... opportunities for collaborative access to cutting-edge drug discovery capabilities, including ...
(Date:10/9/2015)... 9, 2015 Ansun BioPharma announced a presentation ... America ) regarding the compassionate use of DAS181 under ... respirator who was co-infected with influenza and parainfluenza (Abstract ... therapy, O 2 requirement was reduced and the ... to go off the respirator on day 5. Between ...
(Date:10/9/2015)... , Suiza, October 9, 2015 El ,JCA-Mauvernay ... Yutaka Kondo y Junko Takita    ... otorgado a los doctores Yutaka Kondo y ... ,JCA-Mauvernay Award 2015, se ha otorgado a los doctores ...    ™ , una compañía biofarmacéutica global con sede enSuiza, ...
Breaking Medicine Technology:
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The sixth annual cost ... the growth of cybercrime costs for US companies. The New York Times broke down ... With averages showing increases hovering around 20% among the companies surveyed, it only proves ...
(Date:10/10/2015)... ... October 10, 2015 , ... Story Chaser ... It works by reading various classics and inspiring stories and as words drop down ... , The animations are extremely aesthetic and can be interacted with, making it a ...
(Date:10/10/2015)... ... ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, 2015 ... Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be featuring ... and consumers to potentially reduce the chance of error. The report suggests that most ...
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
Breaking Medicine News(10 mins):
... flu outbreak in February in India, the poultry market saw a ... the government assured the people that all the necessary measures are ... the avian flu the sales of chicken and other birds saw ... deaths due to bird flu the sales dips drastically. Every time ...
... of cognitive behavior therapy (CBT) in overcoming depression can ... the University of Pittsburgh School of Medicine. In a ... Journal of Psychiatry, the official journal of the American ... the response to therapy could be a valuable tool ...
... who suffer from severe urinary infection are more likely ... had found a link between acute infections and heart ... infections and clotting in large veins, reported the online ... at the London School of Hygiene and Tropical Medicine ...
... new genes found with breast tumors can predict the outcomes ... the report appearing in he April 1 issue of Clinical ... women at risk for an early relapse of breast cancer. ... discovered as a potential marker of relapse in hormone-receptor positive ...
... from Sheffield University most women still believe one-night stands ... revealed that women of all ages believe that sex ... ,The women community despite achieving liberation still feels ... of desperation or drunkenness. The research which was followed ...
... are still left confused despite making in-depth analysis in ... psychiatric problem that affects the children. ... which is beyond the scientists' control, between 30 percent ... co-existing conditions, so-called comorbidities that make diagnosis and treatment ...
Cached Medicine News:
... Built on the market leading optical performance ... has been optimized for even better views ... system, including a new XHL Xenon Halogen ... cornea and clear, high resolution images of ...
... 2.2 Fr Sur-Catch NT stone retrieval basket raises ... Its unique paired wire design and multi-sizing ... the needs of each patient and procedure. ... for use with the DURTM-8 Elite Ureteroscope and ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
Medicine Products: